Xcout Intel
Mestag Therapeutics
Mestag Therapeutics is an immunotherapy company focusing on fibroblast-immune biology to address critical unmet needs in inflammatory diseases and oncology. The company operates across hubs including Cambridge, United Kingdom, and Ghent, Belgium.
Subscribe to see Mestag Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Mestag Therapeutics at a glance
Mestag Therapeutics is a biotechnology company headquartered in United Kingdom. Its most recent funding round, Seed, raised $40M in March 2026. Xcout tracks 18 named people at Mestag Therapeutics, including Susan Hill (Chief Executive Officer).
Mestag Therapeutics leadership
- Susan HillChief Executive Officer
- Lindsey RolfeChief Medical Officer
- Pascal MerchiersChief Development Officer
- Robert de JongeChief Business Officer
- Ton LogtenbergChair
- Susan HillChief Executive Officer
12 more named people on record for Mestag Therapeutics, with roles, board committees and tenure — see the full roster →
Mestag Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $40M | 5 named | |
| Seed | $45M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Mestag Therapeutics competitors
A few of Mestag Therapeutics's closest competitors — see the full list of competitors and alternatives →
Mission Therapeutics is a drug discovery and development company recognized as a global leader in targeting deubiquitylating enzymes. Founded in 2011, the firm is based at the Babraham Research Campus in Cambridge, United Kingdom.
Engitix is a biotechnology company that utilizes a proprietary platform based on human Extracellular Matrix (ECM) scaffolds to model and study disease biology. The company develops discovery-stage therapeutics targeting fibrosis, inflammation, and solid tumors, and forms partnerships with pharmaceutical and biotech organizations.
Mesentech Inc. is an active for-profit biotechnology company focused on drug pipelines, therapeutic areas, and proprietary technology platforms. Headquartered in Vancouver, British Columbia, Canada, the company operates with a small team specializing in clinical research and development.
4F Biotech is a biotechnology firm focused on developing innovative therapeutic approaches, screening platforms, and diagnostic tools to combat fibrosis and inflammatory processes.
Merus N.V. is a clinical-stage oncology company that discovers and develops antibody treatments for cancer using its proprietary Multiclonics platform. The company serves patients with cancer by advancing innovative therapeutic pipelines. Merus operates as part of Genmab.
NanoGhost is a biotechnology company that develops a targeted drug delivery platform using nanovesicles derived from the cell membranes of mesenchymal stem cells. The company serves the medical and pharmaceutical sectors by creating technologies designed to selectively target cancer and sites of inflammation for improved therapeutic delivery.
Get Mestag Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Mestag Therapeutics in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access